|
1
|
Green AC and Olsen CM: Cutaneous squamous
cell carcinoma: An epidemiological review. Br J Dermatol.
177:373–381. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Behan JW, Sutton A and Wysong A:
Management of skin cancer in the high-risk patient. Curr Treat
Options Oncol. 17:602016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Swick AD, Prabakaran PJ, Miller MC, Javaid
AM, Fisher MM, Sampene E, Ong IM, Hu R, Iida M, Nickel KP, et al:
Cotargeting mTORC and EGFR signaling as a therapeutic strategy in
HNSCC. Mol Cancer Ther. 16:1257–1268. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Iglesias-Bartolome R, Martin D and Gutkind
JS: Exploiting the head and neck cancer oncogenome: Widespread
PI3K-mTOR pathway alterations and novel molecular targets. Cancer
Discov. 3:722–725. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Al-Rohil RN, Tarasen AJ, Carlson JA, Wang
K, Johnson A, Yelensky R, Lipson D, Elvin JA, Vergilio JA, Ali SM,
et al: Evaluation of 122 advanced-stage cutaneous squamous cell
carcinomas by comprehensive genomic profiling opens the door for
new routes to targeted therapies. Cancer. 122:249–257. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Suen JK, Bressler L, Shord SS, Warso M and
Villano JL: Cutaneous squamous cell carcinoma responding serially
to single-agent cetuximab. Anticancer Drugs. 18:827–829. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yang X, Li Z, Wang N, Li L, Song L, He T,
Sun L, Wang Z, Wu Q, Luo N, et al: Curcumin-encapsulated polymeric
micelles suppress the development of colon cancer in vitro and in
vivo. Sci Rep. 5:103222015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Starok M, Preira P, Vayssade M, Haupt K,
Salomé L and Rossi C: EGFR inhibition by curcumin in cancer cells:
A dual mode of action. Biomacromolecules. 16:1634–1642. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wada K, Lee JY, Hung HY, Shi Q, Lin L,
Zhao Y, Goto M, Yang PC, Kuo SC, Chen HW and Lee KH: Novel curcumin
analogs to overcome EGFR-TKI lung adenocarcinoma drug resistance
and reduce EGFR-TKI-induced GI adverse effects. Bioorg Med Chem.
23:1507–1514. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kasi PD, Tamilselvam R, Skalicka-Woźniak
K, Nabavi SF, Daglia M, Bishayee A, Pazoki-Toroudi H and Nabavi SM:
Molecular targets of curcumin for cancer therapy: An updated
review. Tumour Biol. 37:13017–13028. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wu J, Lu WY and Cui LL: Inhibitory effect
of curcumin on invasion of skin squamous cell carcinoma A431 cells.
Asian Pac J Cancer Prev. 16:2813–2818. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Phillips JM, Clark C, Herman-Ferdinandez
L, Moore-Medlin T, Rong X, Gill JR, Clifford JL, Abreo F and Nathan
CO: Curcumin inhibits skin squamous cell carcinoma tumor growth in
vivo. Otolaryngol Head Neck Surg. 145:58–63. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Giannini G, Capalbo C, Ottini L, Buffone
A, de Marchis L, Margaria E, Vitolo D, Ricevuto E, Rinaldi C, Zani
M, et al: Clinical classification of BRCA1 DNA missense variants:
H1686Q is a novel pathogenic mutation occurring in the
ontogenetically invariant THV motif of the N-terminal BRCT domain.
J Clin Oncol. 26:4212–4214; author reply, 4214–4215. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Maubec E, Petrow P, Scheer-Senyarich I,
Duvillard P, Lacroix L, Gelly J, Certain A, Duval X, Crickx B,
Buffard V, et al: Phase II study of cetuximab as first-line
single-drug therapy in patients with unresectable squamous cell
carcinoma of the skin. J Clin Oncol. 29:3419–3426. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Belardinilli F, Capalbo C, Buffone A,
Petroni M, Colicchia V, Ferraro S, Zani M, Nicolussi A, D'Inzeo S,
Coppa A, et al: Validation of the Ion Torrent PGM sequencing for
the prospective routine molecular diagnostic of colorectal cancer.
Clin Biochem. 48:908–910. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Capalbo C, Marchetti P, Coppa A, Calogero
A, Anastasi E, Buffone A, Belardinilli F, Gulino M, Frati P,
Catalano C, et al: Vemurafenib and panitumumab combination tailored
therapy in BRAF-mutated metastatic colorectal cancer: A case
report. Cancer Biol Ther. 15:826–831. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Toll A, Salgado R, Yébenes M,
Martín-Ezquerra G, Gilaberte M, Baró T, Solé F, Alameda F, Espinet
B and Pujol RM: Epidermal growth factor receptor gene numerical
aberrations are frequent events in actinic keratoses and invasive
cutaneous squamous cell carcinomas. Exp Dermatol. 19:151–153. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Schwaederle M, Elkin SK, Tomson BN, Carter
JL and Kurzrock R: Squamousness: Next-generation sequencing reveals
shared molecular features across squamous tumor types. Cell Cycle.
14:2355–2361. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Pickering CR, Zhou JH, Lee JJ, Drummond
JA, Peng SA, Saade RE, Tsai KY, Curry JL, Tetzlaff MT, Lai SY, et
al: Mutational landscape of aggressive cutaneous squamous cell
carcinoma. Clin Cancer Res. 20:6582–6592. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Shimizu T, Izumi H, Oga A, Furumoto H,
Murakami T, Ofuji R, Muto M and Sasaki K: Epidermal growth factor
receptor overexpression and genetic aberrations in metastatic
squamous-cell carcinoma of the skin. Dermatology. 202:203–206.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wollina U: Cetuximab in non-melanoma skin
cancer. Expert Opin Biol Ther. 12:949–956. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Seber S, Gonultas A, Ozturk O and
Yetisyigit T: Recurrent squamous cell carcinoma of the skin treated
successfully with single agent cetuximab therapy. Onco Targets
Ther. 9:945–948. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Takagi M, Kouwaki M, Kawase K, Shinohara
H, Hasegawa Y, Yamada T, Fujiwara I, Sawai H, Nishimura G and
Hasegawa T: A novel mutation Ser344Cys in FGFR3 causes
achondroplasia with severe platyspondyly. Am J Med Genet A.
167A:2851–2854. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
L'Hôte CG and Knowles MA: Cell responses
to FGFR3 signalling: Growth, differentiation and apoptosis. Exp
Cell Res. 304:417–431. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Shtraizent N, Matsui H, Polotskaia A and
Bargonetti J: Hot spot mutation in TP53 (R248Q) causes oncogenic
gain-of-function phenotypes in a breast cancer cell line derived
from an African American patient. Int J Environ Res Public Health.
13:ijerph130100222015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Muller PA and Vousden KH: Mutant p53 in
cancer: New functions and therapeutic opportunities. Cancer Cell.
25:304–317. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Xu J, Wang J, Hu Y, Qian J, Xu B, Chen H,
Zou W and Fang JY: Unequal prognostic potentials of p53
gain-of-function mutations in human cancers associate with
drug-metabolizing activity. Cell Death Dis. 5:e11082014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jobin C, Bradham CA, Russo MP, Juma B,
Narula AS, Brenner DA and Sartor RB: Curcumin blocks
cytokine-mediated NF-kappa B activation and proinflammatory gene
expression by inhibiting inhibitory factor I-kappa B kinase
activity. J Immunol. 163:3474–3483. 1999.PubMed/NCBI
|
|
29
|
Li S, Liu Z, Zhu F, Fan X, Wu X, Zhao H
and Jiang L: Curcumin lowers erlotinib resistance in non-small cell
lung carcinoma cells with mutated EGF receptor. Oncol Res.
21:137–144. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Olivier M, Hollstein M and Hainaut P: TP53
mutations in human cancers: Origins, consequences, and clinical
use. Cold Spring Harb Perspect Biol. 2:a0010082010. View Article : Google Scholar : PubMed/NCBI
|
